Patents by Inventor Michael A. North

Michael A. North has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11046873
    Abstract: Embodiments of this invention relate to methods of adhering in an aqueous environment. More specifically, embodiments of this invention relate to use of a copolymer mimics of mussel adhesive proteins as a high-strength adhesive in aqueous environments.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: June 29, 2021
    Assignee: Purdue Research Foundation
    Inventors: Jonathan James Wilker, Michael A. North, Chelsey A. Del Grosso
  • Publication number: 20190322910
    Abstract: Embodiments of this invention relate to methods of adhering in an aqueous environment. More specifically, embodiments of this invention relate to use of a copolymer mimics of mussel adhesive proteins as a high-strength adhesive in aqueous environments.
    Type: Application
    Filed: August 21, 2017
    Publication date: October 24, 2019
    Applicant: Purdue Research Foundation
    Inventors: Jonathan James Wilker, Michael A. North, Chelsey A. Del Grosso
  • Patent number: 8399647
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: March 19, 2013
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Steven L. Bender, Gerald F. Casperson, Dana D. Hu-Lowe, Xin Jiang, Gang Li, Michael A. North, Jianying Wang, Grant Wickman, Peter Brams, Haichun Huang, Brigitte Devaux, Haibin Chen, Dawn M. Tanamachi, Kristopher Toy, Lan Yang, Tim W. Sproul, Mark Yamanaka
  • Publication number: 20120009622
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.
    Type: Application
    Filed: September 20, 2011
    Publication date: January 12, 2012
    Inventors: Steven L. Bender, Gerald F. Casperson, Dana D. Hu-Lowe, Xin Jiang, Gang Li, Michael A. North, Jianying Wang, Grant Wickman, Peter Brams, Haichun Huang, Brigitte Devaux, Haibin Chen, Dawn M. Tanamachi, Kristopher Toy, Lan Yang, Tim W. Sproul, Mark Yamanaka
  • Publication number: 20110165170
    Abstract: The present disclosure provides isolated antibodies, particularly human antibodies, or antigen binding portions thereof, that bind to osteopontin with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-osteopontin antibodies or antigen binding portions thereof described herein.
    Type: Application
    Filed: August 19, 2010
    Publication date: July 7, 2011
    Applicant: Pfizer Inc.
    Inventors: Trisha Ann Haubrich, Justin Thomas Bingham, Jitesh Pranial Jani, Alessandra Blasina, Kathrin Ladetzki-Baehs, Michael Tesar, Justin Guy Chapman, Dirk Ponsel, Michael A. North
  • Publication number: 20100330078
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.
    Type: Application
    Filed: February 4, 2009
    Publication date: December 30, 2010
    Inventors: STEVEN L. BENDER, GERALD F. CASPERSON, DANA D. HU-LOWE, XIN JIANG, GANG LI, MICHAEL A. NORTH, JIANYING WANG, GRANT WICKMAN, PETER BRAMS, HAICHUN HUANG, BRIGITTE DEVAUX, HAIBIN CHEN, DAWN M. TANAMACHI, KRISTOPHER TOY, LAN YANG, TIM W. SPROUL, MARK YAMANAKA